title: Relapse rate of healed duodenal, prepyloric, and gastric ulcers treated either with sucralfate or cimetidine.
abstract: A multicenter double-blind study was designed to compare the relapse rates of peptic ulcers after initial healing with a cytoprotective agent and a histamine (H2)-receptor antagonist. Patients with endoscopically verified prepyloric or duodenal ulcers were treated with cimetidine 400 mg twice daily or sucralfate 1 g four times daily for a maximum of eight weeks; gastric ulcers were treated for up to 12 weeks. Patients with healed ulcers were followed up to 12 months, during which time anti-ulcer medication was not permitted. Control endoscopy was performed two to four and nine to 11 months after healing and at the time of symptomatic relapse. A total of 258 patients were followed for 12 months; of these, 143 had been previously treated with cimetidine and 115 had been treated with sucralfate. The relapse rates and the median time to relapse did not differ between the two groups. After 12 months, 71 percent of the previously cimetidine-treated patients and 68 percent of the sucralfate-treated patients had experienced a relapse. Smoking significantly increased the relapse rate and shortened the time to relapse in the total study population and among cimetidine-treated patients; it had no such effect in the sucralfate-treated group.
authors.affiliation: Department of Surgery, Skoevde Hospital, Sweden.
authors.forename: H
authors.initials: H
authors.lastname: Glise
authors.forename: L
authors.initials: L
authors.lastname: Carling
authors.forename: B
authors.initials: B
authors.lastname: Hallerbaeck
authors.forename: T
authors.initials: T
authors.lastname: Hallgren
authors.forename: I
authors.initials: I
authors.lastname: Kagevi
authors.forename: J H
authors.initials: JH
authors.lastname: Solhaug
authors.forename: L E
authors.initials: LE
authors.lastname: Svedberg
authors.forename: L
authors.initials: L
authors.lastname: Waehlby
mesh_terms: D002927:Cimetidine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000517:prevention & control; D004724:Endoscopy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000453:epidemiology / Q000517:prevention & control*; D011708:Pylorus; D012907:Smoking / Q000009:adverse effects; D013223:Statistics as Topic; D013276:Stomach Ulcer / Q000517:prevention & control; D013392:Sucralfate / Q000627:therapeutic use*; D013548:Sweden; D014937:Work
chemical_list: D013392:Sucralfate; D002927:Cimetidine